Quarterly Result16 May 2026, 03:31 pm
Tatva Chintan: Board Approves FY26 Results, ₹2 Dividend
AI Summary
The Board of Directors of Tatva Chintan Pharma Chem Ltd approved the audited financial results for the quarter and financial year ended March 31, 2026. They recommended a final dividend of ₹2 (20%) per equity share for FY26, subject to shareholder approval. Additionally, the board approved the appointment of M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor for FY27.
Key Highlights
- Audited financial results (standalone and consolidated) for FY26 approved.
- Final dividend of ₹2 (20%) per share recommended for FY26.
- Zarna Thakar & Associates appointed as Cost Auditor for FY27.
- RSM Astute Consultech Private Limited appointed as Internal Auditor for FY27.
Price Impact
More from TATVA